Hanmi Pharmaceutical Company Limited
Clinical trials sponsored by Hanmi Pharmaceutical Company Limited, explained in plain language.
-
New drug HM15211 shows promise in reversing liver damage in NASH patients
Disease control OngoingThis study tests a new drug called HM15211 in 215 adults with NASH, a liver condition that can lead to scarring. Participants receive either the drug or a placebo for 12 months. The main goal is to see if the drug can reduce liver inflammation and scarring without making it worse…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New weekly shot shows promise for rare low blood sugar disorder
Disease control OngoingThis study tests a new medicine called HM15136 for people aged 2 and older with congenital hyperinsulinism (CHI) who still have low blood sugar despite standard treatments. The medicine is given as a weekly shot for 8 weeks. The goal is to see if it is safe and helps control bloo…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New obesity drug HM15275 enters Mid-Stage trial
Disease control OngoingThis phase 2 study tests an experimental drug called HM15275 for weight loss in 267 adults who are obese or overweight but do not have diabetes. Participants receive either the drug or a placebo as a weekly injection for 36 weeks. The main goal is to see how much body weight chan…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC